Cargando…

Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy

BACKGROUND: Intensity-modulated radiation therapy (IMRT) has been used to limit treatment-related toxicity for patients with anal squamous cell carcinoma (SCC). The treatment outcomes and HPV characteristics for a cohort of patients receiving definitive concurrent chemotherapy and IMRT are reported....

Descripción completa

Detalles Bibliográficos
Autores principales: Foster, Corey C., Lee, Andrew Y., Furtado, Larissa V., Hart, John, Alpert, Lindsay, Xiao, Shu-Yuan, Hyman, Neil H., Sharma, Manish R., Liauw, Stanley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844568/
https://www.ncbi.nlm.nih.gov/pubmed/29522569
http://dx.doi.org/10.1371/journal.pone.0194234
_version_ 1783305258938662912
author Foster, Corey C.
Lee, Andrew Y.
Furtado, Larissa V.
Hart, John
Alpert, Lindsay
Xiao, Shu-Yuan
Hyman, Neil H.
Sharma, Manish R.
Liauw, Stanley
author_facet Foster, Corey C.
Lee, Andrew Y.
Furtado, Larissa V.
Hart, John
Alpert, Lindsay
Xiao, Shu-Yuan
Hyman, Neil H.
Sharma, Manish R.
Liauw, Stanley
author_sort Foster, Corey C.
collection PubMed
description BACKGROUND: Intensity-modulated radiation therapy (IMRT) has been used to limit treatment-related toxicity for patients with anal squamous cell carcinoma (SCC). The treatment outcomes and HPV characteristics for a cohort of patients receiving definitive concurrent chemotherapy and IMRT are reported. MATERIALS AND METHODS: 52 patients with anal SCC were treated with IMRT and concurrent chemotherapy. Radiation was delivered sequentially to the pelvis and inguinal lymph nodes (45 Gy) and anal tumor (median dose, 54 Gy). Multiplex real-time PCR for 7 high-risk HPV subtypes (n = 22) and p16 immunohistochemistry (n = 21, rated on a 0, 1, and 2+ scale) were performed on available specimens. Survival was estimated using Kaplan-Meier analysis, and toxicities were recorded. RESULTS: Median follow-up was 33 months. Three-year freedom from locoregional failure (FFLRF), freedom from distant metastasis (FFDM), freedom from colostomy (FFC), and overall survival (OS) were 94%, 85%, 91%, and 90%, respectively. Acute grade 2+ skin, GI, and GU toxicities occurred in 83%, 71%, and 19% of evaluable patients, respectively. The rates of late grade 2+ GI and GU toxicities for evaluable patients (n = 32) were 28% and 9%, respectively. Of patients with available pathology, 91% and 71% were positive for HPV and p16 (2+), respectively. HPV genotypes included 16 (n = 17), 33 (n = 2), 18 (n = 1), and 45 (n = 1). HPV and p16 status were associated on Chi-square analysis (p = 0.07). Neither HPV nor p16 status was significantly associated with any clinical outcome. For HPV+ patients, 3-year FFLRF, FFDM, FFC, and OS were 100%, 69%, 100%, and 88%, respectively. CONCLUSIONS: In this patient cohort, disease control was excellent for anal SCC treated with definitive concurrent chemotherapy and IMRT, and treatment was well tolerated. HPV and p16 status were not prognostic for treatment outcomes which may be related to our small sample size.
format Online
Article
Text
id pubmed-5844568
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-58445682018-03-23 Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy Foster, Corey C. Lee, Andrew Y. Furtado, Larissa V. Hart, John Alpert, Lindsay Xiao, Shu-Yuan Hyman, Neil H. Sharma, Manish R. Liauw, Stanley PLoS One Research Article BACKGROUND: Intensity-modulated radiation therapy (IMRT) has been used to limit treatment-related toxicity for patients with anal squamous cell carcinoma (SCC). The treatment outcomes and HPV characteristics for a cohort of patients receiving definitive concurrent chemotherapy and IMRT are reported. MATERIALS AND METHODS: 52 patients with anal SCC were treated with IMRT and concurrent chemotherapy. Radiation was delivered sequentially to the pelvis and inguinal lymph nodes (45 Gy) and anal tumor (median dose, 54 Gy). Multiplex real-time PCR for 7 high-risk HPV subtypes (n = 22) and p16 immunohistochemistry (n = 21, rated on a 0, 1, and 2+ scale) were performed on available specimens. Survival was estimated using Kaplan-Meier analysis, and toxicities were recorded. RESULTS: Median follow-up was 33 months. Three-year freedom from locoregional failure (FFLRF), freedom from distant metastasis (FFDM), freedom from colostomy (FFC), and overall survival (OS) were 94%, 85%, 91%, and 90%, respectively. Acute grade 2+ skin, GI, and GU toxicities occurred in 83%, 71%, and 19% of evaluable patients, respectively. The rates of late grade 2+ GI and GU toxicities for evaluable patients (n = 32) were 28% and 9%, respectively. Of patients with available pathology, 91% and 71% were positive for HPV and p16 (2+), respectively. HPV genotypes included 16 (n = 17), 33 (n = 2), 18 (n = 1), and 45 (n = 1). HPV and p16 status were associated on Chi-square analysis (p = 0.07). Neither HPV nor p16 status was significantly associated with any clinical outcome. For HPV+ patients, 3-year FFLRF, FFDM, FFC, and OS were 100%, 69%, 100%, and 88%, respectively. CONCLUSIONS: In this patient cohort, disease control was excellent for anal SCC treated with definitive concurrent chemotherapy and IMRT, and treatment was well tolerated. HPV and p16 status were not prognostic for treatment outcomes which may be related to our small sample size. Public Library of Science 2018-03-09 /pmc/articles/PMC5844568/ /pubmed/29522569 http://dx.doi.org/10.1371/journal.pone.0194234 Text en © 2018 Foster et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Foster, Corey C.
Lee, Andrew Y.
Furtado, Larissa V.
Hart, John
Alpert, Lindsay
Xiao, Shu-Yuan
Hyman, Neil H.
Sharma, Manish R.
Liauw, Stanley
Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy
title Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy
title_full Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy
title_fullStr Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy
title_full_unstemmed Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy
title_short Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy
title_sort treatment outcomes and hpv characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844568/
https://www.ncbi.nlm.nih.gov/pubmed/29522569
http://dx.doi.org/10.1371/journal.pone.0194234
work_keys_str_mv AT fostercoreyc treatmentoutcomesandhpvcharacteristicsforaninstitutionalcohortofpatientswithanalcancerreceivingconcurrentchemotherapyandintensitymodulatedradiationtherapy
AT leeandrewy treatmentoutcomesandhpvcharacteristicsforaninstitutionalcohortofpatientswithanalcancerreceivingconcurrentchemotherapyandintensitymodulatedradiationtherapy
AT furtadolarissav treatmentoutcomesandhpvcharacteristicsforaninstitutionalcohortofpatientswithanalcancerreceivingconcurrentchemotherapyandintensitymodulatedradiationtherapy
AT hartjohn treatmentoutcomesandhpvcharacteristicsforaninstitutionalcohortofpatientswithanalcancerreceivingconcurrentchemotherapyandintensitymodulatedradiationtherapy
AT alpertlindsay treatmentoutcomesandhpvcharacteristicsforaninstitutionalcohortofpatientswithanalcancerreceivingconcurrentchemotherapyandintensitymodulatedradiationtherapy
AT xiaoshuyuan treatmentoutcomesandhpvcharacteristicsforaninstitutionalcohortofpatientswithanalcancerreceivingconcurrentchemotherapyandintensitymodulatedradiationtherapy
AT hymanneilh treatmentoutcomesandhpvcharacteristicsforaninstitutionalcohortofpatientswithanalcancerreceivingconcurrentchemotherapyandintensitymodulatedradiationtherapy
AT sharmamanishr treatmentoutcomesandhpvcharacteristicsforaninstitutionalcohortofpatientswithanalcancerreceivingconcurrentchemotherapyandintensitymodulatedradiationtherapy
AT liauwstanley treatmentoutcomesandhpvcharacteristicsforaninstitutionalcohortofpatientswithanalcancerreceivingconcurrentchemotherapyandintensitymodulatedradiationtherapy